This rare genetic disorder was just treated in the womb for the first time ever
Spinal muscular atrophy is a genetic condition set in motion before birth that causes worsening muscle weakness. There are four types of the disorder, each with varying degrees of severity. However, for those with the most common and severe form, children typically do not live past age 2.
There is no cure, but treatment can help to manage symptoms and prevent complications.
The child's mother was given the drug risdiplam, which is the first oral medication approved to treat the progressive neurodegenerative disorder by the Food and Drug Administration. It is manufactured by Swiss biotech firm Roche.
'Our primary objectives were feasibility, safety and tolerability, so we're very pleased to see that the parent and child are doing well,' Dr. Richard Finkel, the director of the St. Jude Center for Experimental Neurotherapeutics, said in a statement. Scientists at St. Jude Children's Research Hospital led the first in utero treatment. 'The results suggest it would be worthwhile to continue investigating the use of prenatal intervention for SMA.'
Finkel was the corresponding author of the research which was published Wednesday in a letter to the New England Journal of Medicine.
Until now, treatments were given after birth.
'There was still room for improvement,' Finkel told Nature on Thursday.
This progress came about by understanding the cause of spinal muscular atrophy.
Approximately one in every 6,000 babies is born with the disorder. The research hospital noted in a release that it is caused by a lack of survival motor neuron protein. The protein is essential because it enables muscles to receive signals from the nerves, according to Johns Hopkins Medicine. The absence of the protein occurs in around one in every 11,000 births in the U.S. The drug works by helping produce more of the protein.
Because the protein is most needed in the third trimester of fetal development and the first three months of life after birth, St. Jude's says that symptom severity is closely linked with intervention time. So, they launched the clinical protocol to study risdiplam in a single patient. The Food and Drug Administration approved the study.
The parents of the patients had a prior infant born with Type 1 and were known carriers of genetic variants. Testing confirmed that their child would likely be born with Type 1. The idea of giving the drug in utero came from the parents, and doctors gave the mother the drug within the final six weeks of her pregnancy.
After her birth, the baby was diagnosed with several abnormalities that are considered to have occurred before exposure to the drug. She started taking it at a week old and will likely continue to take it for the rest of her life.
They are continuing to monitor her periodically at the research center.
'During the course of the assessment, we really have seen no indication of any signs of SMA,' Finkel said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
New malaria drug for newborn babies offers hope to parents, health workers in Uganda
Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early'. Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (about two to five kilograms). Swissmedic said the treatment, a sweet-tasting tablet that dissolves into a syrup when dropped into liquids like breast milk, was approved in coordination with the World Health Organization (WHO) under a fast-track authorisation process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95 per cent of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. Related Malaria cases surged to 263 million last year amid stalled progress to stop mosquito-borne illness In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than five and pregnant women, the WHO said. Nigeria, Congo, and Uganda – in that order – are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. How the medicine could change malaria treatment The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitising the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. Related Scientists discover drug that could make human blood deadly to mosquitos in fight against malaria During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centres across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria'. In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Related West Nile virus, chikungunya, dengue: Tracking mosquito-borne illnesses across Europe Jane Nabakooza, a pediatrician with Uganda's malaria control programme, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the United States shrank its foreign aid programme earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programmes such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under five years,' Nabakooza said.
CNBC
9 hours ago
- CNBC
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares were up 21% in midday trading after soaring more than 30% earlier Wednesday morning. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
Yahoo
9 hours ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
